Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
HCA vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
HCA vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $95.86B | $16.37B |
| Revenue (TTM) | $75.60B | $21.45B |
| Net Income (TTM) | $6.78B | $1.70B |
| Gross Margin | 41.5% | 42.8% |
| Operating Margin | 15.8% | 16.1% |
| Forward P/E | 14.2x | 10.5x |
| Total Debt | $50.20B | $13.17B |
| Cash & Equiv. | $1.04B | $2.88B |
HCA vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| HCA Healthcare, Inc. (HCA) | 100 | 401.1 | +301.1% |
| Tenet Healthcare Co… (THC) | 100 | 859.0 | +759.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCA vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Rev growth 7.1%, EPS growth 29.0%, 3Y rev CAGR 7.9%
- Lower volatility, beta 0.29, current ratio 0.83x
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 491.5% 10Y total return vs HCA's 452.6%
- PEG 0.32 vs HCA's 0.67
- Lower P/E (10.5x vs 14.2x), PEG 0.32 vs 0.67
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.1% revenue growth vs THC's 3.1% | |
| Value | Lower P/E (10.5x vs 14.2x), PEG 0.32 vs 0.67 | |
| Quality / Margins | 9.0% margin vs THC's 7.9% | |
| Stability / Safety | Beta 0.29 vs THC's 0.71 | |
| Dividends | 0.7% yield; 5-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +25.4% vs HCA's +23.6% | |
| Efficiency (ROA) | 11.3% ROA vs THC's 5.7%, ROIC 19.9% vs 13.2% |
HCA vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HCA vs THC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
THC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 3.5x THC's $21.5B. Profitability is closely matched — net margins range from 9.0% (HCA) to 7.9% (THC). On growth, HCA holds the edge at +6.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $75.6B | $21.5B |
| EBITDAEarnings before interest/tax | $15.5B | $4.3B |
| Net IncomeAfter-tax profit | $6.8B | $1.7B |
| Free Cash FlowCash after capex | $7.7B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +41.5% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +15.8% | +16.1% |
| Net MarginNet income ÷ Revenue | +9.0% | +7.9% |
| FCF MarginFCF ÷ Revenue | +10.2% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.7% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.6% | +87.6% |
Valuation Metrics
THC leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 12.1x trailing earnings, THC trades at a 20% valuation discount to HCA's 15.1x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $95.9B | $16.4B |
| Enterprise ValueMkt cap + debt − cash | $145.0B | $26.7B |
| Trailing P/EPrice ÷ TTM EPS | 15.11x | 12.07x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.18x | 10.53x |
| PEG RatioP/E ÷ EPS growth rate | 0.72x | 0.37x |
| EV / EBITDAEnterprise value multiple | 9.36x | 6.20x |
| Price / SalesMarket cap ÷ Revenue | 1.27x | 0.77x |
| Price / BookPrice ÷ Book value/share | — | 1.89x |
| Price / FCFMarket cap ÷ FCF | 12.46x | 6.47x |
Profitability & Efficiency
HCA leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +19.6% |
| ROA (TTM)Return on assets | +11.3% | +5.7% |
| ROICReturn on invested capital | +19.9% | +13.2% |
| ROCEReturn on capital employed | +27.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 |
| Debt / EquityFinancial leverage | — | 1.47x |
| Net DebtTotal debt minus cash | $49.2B | $10.3B |
| Cash & Equiv.Liquid assets | $1.0B | $2.9B |
| Total DebtShort + long-term debt | $50.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | 5.37x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,145 today (with dividends reinvested), compared to $21,226 for HCA. Over the past 12 months, THC leads with a +25.4% total return vs HCA's +23.6%. The 3-year compound annual growth rate (CAGR) favors THC at 39.2% vs HCA's 16.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -8.7% | -6.3% |
| 1-Year ReturnPast 12 months | +23.6% | +25.4% |
| 3-Year ReturnCumulative with dividends | +57.1% | +169.5% |
| 5-Year ReturnCumulative with dividends | +112.3% | +191.5% |
| 10-Year ReturnCumulative with dividends | +452.6% | +491.5% |
| CAGR (3Y)Annualised 3-year return | +16.3% | +39.2% |
Risk & Volatility
HCA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than THC's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.29x | 0.71x |
| 52-Week HighHighest price in past year | $556.52 | $247.21 |
| 52-Week LowLowest price in past year | $330.00 | $146.31 |
| % of 52W HighCurrent price vs 52-week peak | +77.0% | +75.6% |
| RSI (14)Momentum oscillator 0–100 | 29.2 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.2M |
Analyst Outlook
HCA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates HCA as "Buy" and THC as "Buy". Consensus price targets imply 43.4% upside for THC (target: $268) vs 23.0% for HCA (target: $527). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $527.45 | $268.00 |
| # AnalystsCovering analysts | 46 | 32 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | — |
| Dividend StreakConsecutive years of raises | 5 | 0 |
| Dividend / ShareAnnual DPS | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +10.5% | +8.8% |
THC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). HCA leads in 3 (Profitability & Efficiency, Risk & Volatility).
HCA vs THC: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HCA or THC a better buy right now?
For growth investors, HCA Healthcare, Inc.
(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Tenet Healthcare Corporation (THC) offers the better valuation at 12. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate HCA Healthcare, Inc. (HCA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCA or THC?
On trailing P/E, Tenet Healthcare Corporation (THC) is the cheapest at 12.
1x versus HCA Healthcare, Inc. at 15. 1x. On forward P/E, Tenet Healthcare Corporation is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — HCA or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +191.
5%, compared to +112. 3% for HCA Healthcare, Inc. (HCA). Over 10 years, the gap is even starker: THC returned +491. 5% versus HCA's +452. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCA or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Tenet Healthcare Corporation's 0. 71β — meaning THC is approximately 147% more volatile than HCA relative to the S&P 500.
05Which is growing faster — HCA or THC?
By revenue growth (latest reported year), HCA Healthcare, Inc.
(HCA) is pulling ahead at 7. 1% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: HCA Healthcare, Inc. grew EPS 29. 0% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, HCA leads at 7. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCA or THC?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 6. 6% for Tenet Healthcare Corporation — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus 15. 8% for HCA. At the gross margin level — before operating expenses — THC leads at 82. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCA or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Tenet Healthcare Corporation (THC) trades at 10. 5x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 3. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 43. 4% to $268. 00.
08Which pays a better dividend — HCA or THC?
In this comparison, HCA (0.
7% yield) pays a dividend. THC does not pay a meaningful dividend and should not be held primarily for income.
09Is HCA or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +452. 6% 10Y return). Both have compounded well over 10 years (HCA: +452. 6%, THC: +491. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCA and THC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
HCA pays a dividend while THC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.